📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. (2016)

First Author: Lochhead PA
Attributed to:  Discovery of ERK5 inhibitors for biomarker-driven clinical evaluation in cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1080/15384101.2015.1120915

PubMed Identifier: 26959608

Publication URI: http://europepmc.org/abstract/MED/26959608

Type: Journal Article/Review

Volume: 15

Parent Publication: Cell cycle (Georgetown, Tex.)

Issue: 4

ISSN: 1551-4005